211 related articles for article (PubMed ID: 30254209)
1. E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer.
Xiang S; Wang Z; Ye Y; Zhang F; Li H; Yang Y; Miao H; Liang H; Zhang Y; Jiang L; Hu Y; Zheng L; Liu X; Liu Y
Oncogene; 2019 Feb; 38(8):1269-1281. PubMed ID: 30254209
[TBL] [Abstract][Full Text] [Related]
2. Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer.
Drucker E; Holzer K; Pusch S; Winkler J; Calvisi DF; Eiteneuer E; Herpel E; Goeppert B; Roessler S; Ori A; Schirmacher P; Breuhahn K; Singer S
Cell Commun Signal; 2019 Nov; 17(1):159. PubMed ID: 31783876
[TBL] [Abstract][Full Text] [Related]
3. mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cells.
Wang CI; Chen YY; Wang CL; Yu JS; Chang YS; Yu CJ
Oncotarget; 2016 May; 7(18):25432-42. PubMed ID: 27009856
[TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer.
Wang CI; Chien KY; Wang CL; Liu HP; Cheng CC; Chang YS; Yu JS; Yu CJ
Mol Cell Proteomics; 2012 Nov; 11(11):1105-22. PubMed ID: 22843992
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7.
Ye YY; Mei JW; Xiang SS; Li HF; Ma Q; Song XL; Wang Z; Zhang YC; Liu YC; Jin YP; Hu YP; Jiang L; Liu FT; Zhang YJ; Hao YJ; Liu YB
Cell Death Dis; 2018 Mar; 9(3):410. PubMed ID: 29540696
[TBL] [Abstract][Full Text] [Related]
6. Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression.
Liu B; Shats I; Angus SP; Gatza ML; Nevins JR
J Biol Chem; 2013 Aug; 288(34):24581-9. PubMed ID: 23853115
[TBL] [Abstract][Full Text] [Related]
7. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
8. KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a.
Huang L; Wang HY; Li JD; Wang JH; Zhou Y; Luo RZ; Yun JP; Zhang Y; Jia WH; Zheng M
Cell Death Dis; 2013 Aug; 4(8):e745. PubMed ID: 23907459
[TBL] [Abstract][Full Text] [Related]
9. KPNA2 is a promising biomarker candidate for esophageal squamous cell carcinoma and correlates with cell proliferation.
Ma S; Zhao X
Oncol Rep; 2014 Oct; 32(4):1631-7. PubMed ID: 25109899
[TBL] [Abstract][Full Text] [Related]
10. Karyopherin α 2 promotes proliferation, migration and invasion through activating NF-κB/p65 signaling pathways in melanoma cells.
Yang F; Li S; Cheng Y; Li J; Han X
Life Sci; 2020 Jul; 252():117611. PubMed ID: 32243925
[TBL] [Abstract][Full Text] [Related]
11. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.
Tan S; Ding K; Li R; Zhang W; Li G; Kong X; Qian P; Lobie PE; Zhu T
Breast Cancer Res; 2014 Apr; 16(2):R40. PubMed ID: 24735615
[TBL] [Abstract][Full Text] [Related]
12. Karyopherin alpha 2 is a novel prognostic marker and a potential therapeutic target for colon cancer.
Zhang Y; Zhang M; Yu F; Lu S; Sun H; Tang H; Peng Z
J Exp Clin Cancer Res; 2015 Dec; 34():145. PubMed ID: 26626145
[TBL] [Abstract][Full Text] [Related]
13. microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway.
Wang C; Li S; Xu J; Niu W; Li S
Br J Biomed Sci; 2019 Jan; 76(1):17-23. PubMed ID: 30203720
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of KPNA2 is associated with a poor prognosis and contributes to OCT4 nuclear transportation in bladder cancer.
Zhou J; Dong D; Cheng R; Wang Y; Jiang S; Zhu Y; Fan L; Mao X; Gui Y; Li Z; Li X; Shi B
Oncotarget; 2016 Nov; 7(45):72767-72776. PubMed ID: 27611951
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression.
Li XL; Jia LL; Shi MM; Li X; Li ZH; Li HF; Wang EH; Jia XS
J Transl Med; 2013 Sep; 11():232. PubMed ID: 24070213
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
Reimer D; Sadr S; Wiedemair A; Stadlmann S; Concin N; Hofstetter G; Müller-Holzner E; Marth C; Zeimet AG
Clin Cancer Res; 2007 Jan; 13(1):144-51. PubMed ID: 17200349
[TBL] [Abstract][Full Text] [Related]
17. MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4.
Lin J; Zhang L; Huang H; Huang Y; Huang L; Wang J; Huang S; He L; Zhou Y; Jia W; Yun J; Luo R; Zheng M
Oncotarget; 2015 Sep; 6(27):23793-806. PubMed ID: 26204489
[TBL] [Abstract][Full Text] [Related]
18. E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation.
Endo-Munoz L; Dahler A; Teakle N; Rickwood D; Hazar-Rethinam M; Abdul-Jabbar I; Sommerville S; Dickinson I; Kaur P; Paquet-Fifield S; Saunders N
Cancer Res; 2009 Mar; 69(5):1800-8. PubMed ID: 19223542
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-139 inhibits hepatocellular carcinoma cell growth through down-regulating karyopherin alpha 2.
Zan Y; Wang B; Liang L; Deng Y; Tian T; Dai Z; Dong L
J Exp Clin Cancer Res; 2019 May; 38(1):182. PubMed ID: 31046781
[TBL] [Abstract][Full Text] [Related]
20. The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.
di Iasio MG; Zauli G
Invest New Drugs; 2013 Apr; 31(2):458-60. PubMed ID: 23054209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
